Clinical Evaluation of Florbetapir F 18 (18F-AV-45)



Status:Completed
Conditions:Alzheimer Disease, Cognitive Studies, Neurology
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:18 - Any
Updated:7/20/2018
Start Date:December 2009
End Date:May 3, 2017

Use our guide to learn which trials are right for you!

This protocol is designed to standardize imaging studies using florbetapir F 18 PET to
provide information on amyloid burden in subjects participating in other studies (companion
protocol) such as longitudinal studies of aging and studies of biomarkers for
neurodegenerative diseases.


Subjects who meet all of the following criteria are eligible to enroll in this study:

1. Male or female subjects at least 18 years of age;

2. Subjects who sign an IRB approved informed consent prior to any study procedures.
Where subjects are deemed incapable of informed consent, a legally authorized
representative may provide consent, with the subject's documented assent; and

3. Subjects who in the opinion of the investigator can tolerate the PET scan procedures.

Subjects will be excluded from enrollment if they:

1. Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine
disturbances as indicated by history, which in the opinion of the investigator might
pose a potential safety risk to the subject;

2. Have current clinically significant cardiovascular disease. Clinically significant
cardiovascular disease usually includes one or more of the following:

- cardiac surgery or myocardial infarction within the last 4 weeks;

- unstable angina;

- acute decompensated congestive heart failure or class IV heart failure;

- current significant cardiac arrhythmia or conduction disturbance, particularly
those resulting in ventricular fibrillation, or causing syncope, or near syncope;

- uncontrolled high blood pressure; or

- QTc > 450 msec (by history or for patients with cardiac disease by screening
evaluation in companion study)

Before enrolling a patient with any of the above conditions, the investigator must
have performed a cardiac evaluation and obtain permission from the sponsor.

3. Have a history of drug or alcohol abuse within the last year, or prior prolonged
history of abuse;

4. Women of childbearing potential who are not surgically sterile, not refraining from
sexual activity or not using reliable methods of contraception. Women of childbearing
potential must not be pregnant (negative urine beta-hCG at the time of screening and
negative urine beta-hCG on the day of imaging) or breastfeeding at screening. Women
must avoid becoming pregnant, and must agree to refrain from sexual activity or to use
reliable contraceptive methods for 24 hours following administration of Florbetapir F
18 Injection ( such as oral contraceptives for at least three months or an IUD for at
least two months prior to the start of the screening visit, or various barrier
methods, e.g., diaphragm or combination condom and spermicide);

5. Have a history of relevant severe drug allergy or hypersensitivity (Relevant severe
drug allergies should be determined by the PI, and any questions about a subject's
eligibility can be directed to Avid. If a subject has a history of severe drug
allergies, it may be dangerous for them to participate in a study);

6. Are patients who have received an investigational medication under an FDA IND protocol
within the last 30 days. Additionally, the time between the last dose of the previous
experimental medication and enrollment (completion of screening assessments) must be
at least equal to 5 times the terminal half-life of the previous experimental
medication. Patients who have ever participated in an experimental study with an
amyloid targeting therapy (e.g., immunotherapy, secretase inhibitor) may not be
enrolled without prior sponsor approval unless it can be demonstrated that the patient
received only placebo in the course of the trial;

7. Are patients with current clinically significant unstable medical comorbidities, as
indicated by history or physical exam, that pose a potential safety risk to the
subject.

8. Are patients who have received a radiopharmaceutical for imaging or therapy within the
past 24 hours prior to the imaging session for this study. If another radiotracer is
required in the companion protocol, patients may be able to receive a
radiopharmaceutical for imaging or therapy within the 24 hours prior to the imaging
session with prior sponsor approval and at the discretion of the investigator.; and

9. Are patients who, in the opinion of the investigator, are otherwise unsuitable for a
study of this type.

If at the time of enrollment subjects do not meet all eligibility criteria, the subjects
may still be enrolled if documentation is provided demonstrating that the subject will meet
all criteria at the time of the first imaging procedure.
We found this trial at
31
sites
Durham, North Carolina 27710
(919) 684-8111
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Dean Wong
Phone: 410-955-8433
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
Principal Investigator: Helena Chui
Phone: 323-865-9949
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Emily Rogalski
Phone: 312-503-1155
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Dallas, Texas 75231
Principal Investigator: Denise Park
Phone: 972-883-3255
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75231
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1 Airport Road
Davis, California 95616
Principal Investigator: John Olichney
Phone: 916-734-5223
?
mi
from
Davis, CA
Click here to add this to my saved trials
Irvine, California 92868
?
mi
from
Irvine, CA
Click here to add this to my saved trials
Jacksonville, Florida 32216
Principal Investigator: Neill Graff-Radford
Phone: 904-953-7103
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Jacksonville, Florida 32216
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Kansas
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Knoxville, Tennessee 37920
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Miami Beach, Florida 33140
Principal Investigator: Ranjan Duara
Phone: 305-674-2543
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Nashville, Tennessee 37212
?
mi
from
Nashville, TN
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19107
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Roderic Eckenhoff
Phone: 215-294-9172
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85006
Principal Investigator: Eric Reiman
Phone: 602-839-6999
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phoenix, Arizona 85006
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
345 Blackstone Blvd
Providence, Rhode Island 02906
(401) 455-6200
Principal Investigator: Stephen Salloway
Phone: 401-455-6403
Butler Hospital Founded in 1844, Butler Hospital is the state's only non-profit, free-standing psychiatric hospital...
?
mi
from
Providence, RI
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
50 Beale Street
San Francisco, California 94121
Principal Investigator: Marek Brzezinski
Phone: 415-750-2069
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
50 Beale Street
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
50 Beale Street
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Sun City, Arizona 85351
?
mi
from
Sun City, AZ
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials